Eskata is a drug owned by Aclaris Therapeutics Inc. It is protected by 6 US drug patents filed from 2018 to 2020. Out of these, 5 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 04, 2035. Details of Eskata's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9675639 | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(10 years from now) | Active |
| US10493103 | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | Active |
| US10729720 | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | Active |
| US10098910 | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | Active |
| US9980983 | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | Active |
| US7381427 | Seborrheic keratosis treatment |
Jun, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eskata's patents.
Latest Legal Activities on Eskata's Patents
Given below is the list of recent legal activities going on the following patents of Eskata.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 08 Jan, 2024 | US10493103 |
| Maintenance Fee Reminder Mailed Critical | 24 Jul, 2023 | US10493103 |
| Expire Patent Critical | 21 Nov, 2022 | US10098910 |
| Post Issue Communication - Certificate of Correction | 18 Nov, 2022 | US9675639 |
| Change in Power of Attorney (May Include Associate POA) Critical | 19 Sep, 2022 | US9675639 |
| Email Notification Critical | 19 Sep, 2022 | US9675639 |
| Correspondence Address Change Critical | 13 Sep, 2022 | US9675639 |
| Maintenance Fee Reminder Mailed Critical | 06 Jun, 2022 | US10098910 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Apr, 2022 | US10493103 |
| Email Notification Critical | 14 Apr, 2022 | US10493103 |
FDA has granted several exclusivities to Eskata. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Eskata, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Eskata.
Exclusivity Information
Eskata holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Eskata's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 14, 2020 |
US patents provide insights into the exclusivity only within the United States, but Eskata is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Eskata's family patents as well as insights into ongoing legal events on those patents.
Eskata's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Eskata's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 04, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Eskata Generics:
There are no approved generic versions for Eskata as of now.
About Eskata
Eskata is a drug owned by Aclaris Therapeutics Inc. It is used for treating raised seborrheic keratoses. Eskata uses Hydrogen Peroxide as an active ingredient. Eskata was launched by Aclaris in 2017.
Approval Date:
Eskata was approved by FDA for market use on 14 December, 2017.
Active Ingredient:
Eskata uses Hydrogen Peroxide as the active ingredient. Check out other Drugs and Companies using Hydrogen Peroxide ingredient
Treatment:
Eskata is used for treating raised seborrheic keratoses.
Dosage:
Eskata is available in solution form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40% | SOLUTION | Discontinued | TOPICAL |